Literature DB >> 8861994

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.

J E Siegel1, M C Weinstein, L B Russell, M R Gold.   

Abstract

OBJECTIVE: This article, the third in a 3-part series, describes recommendations for the reporting of cost-effective analyses (CEAs) intended to improve the quality and accessibility of CEA reports. PARTICIPANTS: The Panel on Cost-Effectiveness in Health and Medicine, a nonfederal panel with expertise in CEA, clinical medicine, ethics, and health outcomes measurement, convened by the US Public Health Service. EVIDENCE: The panel reviewed the theoretical foundations of CEA, current practices, alternative methods, published critiques of CEAs, and criticisms of general CEA methods and reporting practices. CONSENSUS PROCESS: The panel developed recommendations through 2 1/2 years of discussions. Comments on preliminary drafts were solicited from federal government methodologists, health agency officials, and academic methodologists.
CONCLUSIONS: These recommendations are proposed to enhance the transparency of study methods, assist analysts in providing complete information, and facilitate the presentation of comparable cost-effectiveness results across studies. Adherence to reporting conventions and attention to providing information required to understand and interpret study results will improve the relevance and accessibility of CEAs.

Entities:  

Mesh:

Year:  1996        PMID: 8861994     DOI: 10.1001/jama.276.16.1339

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  269 in total

Review 1.  Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?

Authors:  C Bombardier; A Maetzel
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Cost utility analysis of radiographic screening for an orbital foreign body before MR imaging.

Authors:  D J Seidenwurm; C H McDonnell; N Raghavan; J Breslau
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

3.  Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

Authors:  Andreas Laupacis
Journal:  CMAJ       Date:  2002-01-08       Impact factor: 8.262

4.  Economic analysis of randomized, controlled trials.

Authors:  G H Lyman
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 5.  AIDS policy modeling for the 21st century: an overview of key issues.

Authors:  M S Rauner; M L Brandeau
Journal:  Health Care Manag Sci       Date:  2001-09

6.  Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).

Authors:  M Iskedjian; K Trakas; C A Bradley; A Addis; K Lanctôt; D Kruk; A L Ilersich; T R Einarson
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

7.  Evaluating the benefits of increasing measles immunization rates.

Authors:  J Zwanziger; P G Szilagyi; P Kaul
Journal:  Health Serv Res       Date:  2001-10       Impact factor: 3.402

8.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  David Moher; Kenneth F Schulz; Douglas G Altman
Journal:  Clin Oral Investig       Date:  2003-01-31       Impact factor: 3.573

9.  Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

Authors:  Takeru Shiroiwa; Yoshiharu Motoo; Kiichiro Tsutani
Journal:  Mol Diagn Ther       Date:  2010-12-01       Impact factor: 4.074

10.  Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?

Authors:  E Losina; M E Daigle; L G Suter; D J Hunter; D H Solomon; R P Walensky; J M Jordan; S A Burbine; A D Paltiel; J N Katz
Journal:  Osteoarthritis Cartilage       Date:  2013-02-04       Impact factor: 6.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.